Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Orgovyx (relugolix) is indicated for the treatment of adult patients with advanced prostate cancer.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). 3. 12-Month Castration Rate: Relugolix had a risk ratio (RR) of 1.09 (95% CrI: 0.95-1.23) and Degarelix had a RR of 0.98 (95% CrI: 0.91-1.06) compared to GnRH agonists, indicating no significant difference in achieving the 12-month castration rate. However, the 480 mg dose of degarelix was significantly associated with a lower castration rate (RR 0.46, 95% CrI: 0.07-0.92). ^[1-2]
• Comparative Effectiveness: Relugolix and degarelix were comparable in achieving the 12-month castration rate, with relugolix showing a slight, non-significant edge in efficacy ranking analyses.
• Subgroup Analysis: A significant finding was noted for the 480 mg dose of degarelix, which had a lower 12-month castration rate compared to other doses. No specific population types were mentioned in the subgroup analyses.
• GnRH antagonists (relugolix and degarelix) were associated with significantly fewer adverse cardiovascular events, cardiovascular deaths, and all-cause mortality compared to GnRH agonists, with pooled risk ratios of 0.57 (95% CI: 0.39-0.81), 0.49 (95% CI: 0.25-0.96), and 0.48 (95% CI: 0.28-0.83), respectively.
• Relugolix and degarelix demonstrated no significant differences in overall adverse events and serious adverse events when compared to GnRH agonists, with relugolix having RRs of 0.99 (95% CrI: 0.6-1.6) for all AEs and 0.72 (95% CrI: 0.4-1.3) for serious AEs, and degarelix having RRs of 1.1 (95% CrI: 0.75-1.35) for all AEs and 1.05 (95% CrI: 0.42-2.6) for serious AEs.
• There is no population types or subgroups information available in the reviewed studies.